Explore kidney identity, molecular injury markers and morphology over time through cisplatin and doxorubicin studies.
STUDY EVIDENCE
Kidney organoid studies cover nephron identity and cisplatin molecular readouts in H9 hESC-derived organoids, together with morphology over time during doxorubicin exposure in a human kidney organoid system. We select the culture approach, dose, timing and injury endpoints for each candidate.
E-cadherin, LRP2 and Nephrin combine with morphology and histology to confirm nephron-associated identity before injury studies.
Confirms model suitability and cell-type-relevant endpoints
RT-qPCR after cisplatin exposure profiles expression responses in KIM-1, H2AFX, IL-8, IL-1β and PUMA, supporting selection of kidney-injury, inflammatory and stress-related endpoints for follow-on confirmation.
Guides molecular-injury endpoints and follow-up priorities
Bright-field views before exposure and at 24 and 48 hours provide morphological context for injury timing and downstream assays.
Guides observation windows and sampling time pointsINTERPRETATION
Confirms model identity, compares the timing and molecular dimensions of injury, and selects follow-on endpoints for dose, mechanism and recovery studies.
Kidney safety studies can draw on H9-derived cisplatin readouts or human kidney organoid doxorubicin evidence, then align dose, timing and mechanism endpoints within the selected culture approach.
Compare dose and exposure duration, add mechanism and recovery endpoints, and confirm findings across independent batches.
Related models and services
Study planning
Early safety screening or kidney-injury mechanism work
Candidate, exposure design, known risk and endpoints to compare
Model identity checks, compound exposure, morphology and injury assays
Model QC, dose conditions, images, assay data and study report
Identify kidney injury signals and define recommended follow-up studies
Candidate properties, exposure range, batch consistency and translational-study planning
PROJECT DISCUSSION
Tell us which model, assay or finding you want to extend. Our scientists will adapt the approach to your candidate, samples and decision point.
Explore kidney identity, molecular injury markers and morphology over time through cisplatin and doxorubicin studies.
STUDY EVIDENCE
Kidney organoid studies cover nephron identity and cisplatin molecular readouts in H9 hESC-derived organoids, together with morphology over time during doxorubicin exposure in a human kidney organoid system. We select the culture approach, dose, timing and injury endpoints for each candidate.
E-cadherin, LRP2 and Nephrin combine with morphology and histology to confirm nephron-associated identity before injury studies.
Confirms model suitability and cell-type-relevant endpointsRT-qPCR after cisplatin exposure profiles expression responses in KIM-1, H2AFX, IL-8, IL-1β and PUMA, supporting selection of kidney-injury, inflammatory and stress-related endpoints for follow-on confirmation.
Guides molecular-injury endpoints and follow-up prioritiesBright-field views before exposure and at 24 and 48 hours provide morphological context for injury timing and downstream assays.
Guides observation windows and sampling time pointsINTERPRETATION
Confirms model identity, compares the timing and molecular dimensions of injury, and selects follow-on endpoints for dose, mechanism and recovery studies.
Kidney safety studies can draw on H9-derived cisplatin readouts or human kidney organoid doxorubicin evidence, then align dose, timing and mechanism endpoints within the selected culture approach.
Compare dose and exposure duration, add mechanism and recovery endpoints, and confirm findings across independent batches.
Related models and services
Study planning
Early safety screening or kidney-injury mechanism work
Candidate, exposure design, known risk and endpoints to compare
Model identity checks, compound exposure, morphology and injury assays
Model QC, dose conditions, images, assay data and study report
Identify kidney injury signals and define recommended follow-up studies
Candidate properties, exposure range, batch consistency and translational-study planning
PROJECT DISCUSSION
Tell us which model, assay or finding you want to extend. Our scientists will adapt the approach to your candidate, samples and decision point.
